Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. - Wikidata - awgldk - TriplyDB

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

http://www.wikidata.org/entity/Q42999969

about

Aminoadamantanes for chronic hepatitis C Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C Viral Determinants of Resistance to Treatment in Patients with Hepatitis C Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.Triple antiviral therapy in HCV positive patients who failed prior combination therapy Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Treatment of hepatitis C virus infection Treatment of viral hepatitis--2001.Experimental and emerging therapies for chronic hepatitis C virus infection.Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).Management issues in chronic viral hepatitis: hepatitis C.Management of viral hepatitis C.Treatment of recurrent hepatitis C.Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.Therapeutic modalities in hepatitis C: challenges and development.Amantadine in treatment of chronic hepatitis C virus infection?Hepatitis C virus and its renal manifestations: a review and update Treating viral hepatitis C: efficacy, side effects, and complications.Distribution and dynamics of adamantanes in a lipid bilayer A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral target.Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.Treatment of chronic hepatitis C patients not responding to combination therapy with ribavirin and interferon alpha--hype or hope?A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging.Clearance kinetics of hepatitis C virus under different antiviral therapies.High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C.Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine.Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine

P2860

Q24194770-AB9CC332-0E07-4B37-B9BE-E000C3CFB366 Q27477967-AE9023BB-2189-4C1C-B0D8-66F4B6B79CA0 Q27478062-C2B08A12-E7AC-4D53-A938-20F73C544F6A Q30746310-1D9F9BE9-6CF8-44A8-A271-FE39C3FE5737 Q33869358-360133C4-3351-4B38-BD8B-94F7259D4014 Q33947375-4BA9FA88-19C7-4350-BAF4-9EFD966AD90E Q34099424-10EAF1C4-D16B-4C79-92BC-E26AE96FBA7C Q34390398-9284D3E5-C7A2-4448-829D-20719EA8CF0B Q34481629-6056EDF4-ED5B-4DA6-AA90-321BFEE0807B Q34605831-27BFCFDD-3457-4B24-8BCC-FBE435E65A42 Q34619371-37CF3B93-19B8-4A5F-AA4D-DEC79110CB78 Q34631375-F3F1BC23-71D9-41AA-BB12-7DEFBFA052C9 Q34936164-E273EFE8-26DF-4B76-9E50-77F1D7AA0D5E Q35588125-AE5D0D90-2C11-42A2-80EF-A57D8CC18ED8 Q35595630-1EF5A1A9-06B4-418D-886F-4FB6A3E9F27B Q36011951-E1731528-9FBA-49DC-973F-AFF636D74350 Q36234125-078E29A8-0690-4706-A310-173E9DE18751 Q36496970-34778DC4-541F-4E7A-9E51-58B2E16827D3 Q36564615-AB1A6084-02B3-4B0B-AF18-307DE6F44C81 Q37008274-2B89E835-5A8F-4F33-966F-0B109CCE5F07 Q37105582-36BA9717-8A6C-4EA5-858B-64C29088710F Q37860404-5C99BDF9-E145-4C55-B73F-CD50DBC53F47 Q38990471-C50284C0-E7AD-40DC-B084-6A9E783F415D Q42699415-130A0B2D-F45B-432C-BF65-B8C836269DA1 Q42992074-E00FEA5A-C2E4-45B6-9702-01F34809A82C Q43005161-C3973D3D-48B4-4CAE-B394-D3021CBBDAFA Q43033022-DBB301A5-ADDD-453B-B644-6241FDB234A1 Q43649889-2A982B1E-AC15-4418-9890-5A325C0945F3 Q49216363-53D19C94-4155-42BA-8E10-2E94EAF363FE Q50574338-A74D80E3-62EC-40C4-8F64-D250BA00FA7F Q50580456-6EFC9F92-765E-4A6C-B58D-75A445884FDC Q50584975-D6BE9B13-2534-4A90-B9FB-84ADF2386928 Q50585032-07078CC9-D645-4FC3-810D-352A80B977CB Q56454915-E29EB1D4-67CC-48EA-B745-B08BF46436F7

P2860

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

http://www.wikidata.org/entity/Q42999969

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh-hant

name

Triple antiviral therapy as a ...... esponsive chronic hepatitis C.

@en

Triple antiviral therapy as a ...... esponsive chronic hepatitis C.

@nl

type

label

Triple antiviral therapy as a ...... esponsive chronic hepatitis C.

@en

Triple antiviral therapy as a ...... esponsive chronic hepatitis C.

@nl

prefLabel

Triple antiviral therapy as a ...... esponsive chronic hepatitis C.

@en

Triple antiviral therapy as a ...... esponsive chronic hepatitis C.

@nl

P1433

Q42999969-5E2E415B-3E04-462D-9FBA-1DA60DDD5AAB

P1476

Q42999969-2B72C969-1058-42DE-AAAA-9535882CCFC5

P2093

Q42999969-0FDDE748-6C2B-4002-BB70-8D3BB6DE6150

Q42999969-A2B481C1-5A40-4BFF-A0D0-EB8B07B06167

Q42999969-B273CDE6-C8F4-4ABB-8E91-E41078B4E594

Q42999969-BBE32B00-0838-4B47-84C8-8848E67FC80F

Q42999969-EC60E3D4-53A8-4C98-9A9E-59301F320CFE

P304

Q42999969-8EFB37E1-62EA-43BB-9524-DBB27449E610

P31

Q42999969-8E94B36D-2488-4DD8-842A-C2194EBBB6B4

P356

Q42999969-15A58491-4B8F-457A-8A62-29A4539277A6

P407

Q42999969-02D11700-19C2-44A5-A8D8-676220351E3A

P433

Q42999969-E301FAEE-B5B3-4207-927C-C32668DAEB84

P478

Q42999969-39135D62-8505-41F6-9715-66DE01F07C83

P577

Q42999969-D2E48DA4-10DD-4FBB-9F35-B68806AADA6D

P5875

Q42999969-2AAE9C8E-5CC3-4EB2-9312-BBD025C85308

P698

Q42999969-E931CDE2-6579-4E26-A60F-B6F5843A3CEE

P356

JHEP.2000.16235

P1433

P1476

Triple antiviral therapy as a ...... esponsive chronic hepatitis C.

@en

P2093

Bolondi L

http://www.w3.org/2001/XMLSchema#string

Brillanti S

http://www.w3.org/2001/XMLSchema#string

Foli M

http://www.w3.org/2001/XMLSchema#string

Levantesi F

http://www.w3.org/2001/XMLSchema#string

Masi L

http://www.w3.org/2001/XMLSchema#string

P304

630-634

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2000.16235

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12362437

http://www.w3.org/2001/XMLSchema#string

P698

10960460

http://www.w3.org/2001/XMLSchema#string